Navigation Links
PTC Therapeutics to Showcase Breadth of Pipeline at Upcoming R&D Day
Date:10/19/2013

SOUTH PLAINFIELD, N.J., Oct. 18, 2013 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that it will hold its first R&D Day on Friday, October 25, 2013 from 8:30 a.m. to 12:00 p.m. ET at the Four Seasons Hotel in New York City. Members of PTC's senior management and research teams will provide a corporate update and in-depth reviews of the company's scientific platforms and R&D programs.

(Logo:  http://photos.prnewswire.com/prnh/20010919/PTCLOGO)

A live webcast of the event will be available on the Events and Presentations page under the investor relations section of PTC Therapeutics' website at www.ptcbio.com. The presentation will be archived for 2 weeks following the presentation. It is recommended that users connect to PTC's website several minutes prior to the start of the webcast to ensure a timely connection. 

About PTC Therapeutics, Inc.       
PTC is biopharmaceutical company focused on the discovery and development of orally administered, proprietary small molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are essential to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare disorders, oncology and infectious diseases. PTC has developed proprietary technologies that it applies in its drug discovery activities and form the basis for collaborations with leading biopharmaceutical companies. For more information on the company, please visit our website www.ptcbio.com  

Forward Looking Statements:                   
Any statements in this press release about future expectations, plans and prospects for the Company, the development of and potential market for the Company's product candidates and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan" "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Forward-looking statements involve substantial risks and uncertainties that could cause our future results, performance or achievements to differ significantly from those expressed or implied by these forward-looking statements. Such risks and uncertainties include, among others, those related to the initiation and conduct of clinical trials, availability of data from clinical trials, expectations for regulatory approvals, our scientific approach and general development progress, the availability or commercial potential of our product candidates and other factors discussed in the "Risk Factors" in the most recent Quarterly Report, which is on file with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views only as of the date of this release. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this release.


'/>"/>
SOURCE PTC Therapeutics, Inc.
Copyright2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2017)... July 27, 2017  West Pharmaceutical Services, Inc. (NYSE: ... for the second-quarter 2017 and updated financial guidance for ... Second-Quarter 2017 Highlights Reported net sales ... the prior-year quarter. Net sales at constant currency (organic) ... EPS was $0.51, compared to $0.60 in the prior-year ...
(Date:7/26/2017)... 2017  Radium Medical Aesthetics, a leading medical aesthetic clinic in ... by effectively addressing several skin conditions from the inside. ... and more fragile. The skin becomes more transparent due to the ... harmful UV rays from the sun contributes to aging skin, causing ... ...
(Date:7/26/2017)... The Galien Foundation announced today the 2017 11 ... Award Nominees. Counted among the global health innovation industry,s most ... technology product achievement that improves the human condition. ... be U.S. Food and Drug Administration (FDA) approved for market ... impact human health. Sales data are not considered by the ...
Breaking Medicine Technology:
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... says will lift the veil on false teachings pertaining to the mother of the Savior ... teach, you see a far different picture of the role of this historical woman. ...
(Date:8/18/2017)... ... 2017 , ... “Our Mountains to Climb: A Journey of Love and Faith ... together through the faith they shared to overcome struggles in life. “Our Mountains to ... author, Barbara J. Corcoran, a retired teacher and happily married since 1999; the author’s ...
(Date:8/18/2017)... ... August 18, 2017 , ... “Depressed: Super Heroes of the ... to reflect upon the stories and the relevance these tales may have on the ... Jessica Linhart, a former special education teacher, Jessica spends much of her time enjoying ...
(Date:8/18/2017)... , ... August 18, 2017 , ... “Steve the Snake”: ... “Steve the Snake” is the creation of published author, Harold Flash Haskins Jr., a ... a Department of Defense police officer. , “I write moral-based short stories for children ...
(Date:8/17/2017)... ... August 17, 2017 , ... ... announces that it will feature the National Council for Therapeutic Recreation Certification (NCTRC), ... information. , Established in 1981, NCTRC is a non-profit, international organization dedicated to ...
Breaking Medicine News(10 mins):